Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

CB-03-01 is considered too costly and lacks a proper delivery method, making it less viable compared to RU58841, which has shown effectiveness with minimal side effects. Finasteride caused a drop in libido for one user.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

A user experienced significant hair regrowth after 4 months using topical finasteride and minoxidil, along with dermastamping and biotin supplements, without side effects. They are not considering a hair transplant due to the success of this regimen.

The user is experiencing positive hair regrowth results after four months of using oral finasteride (1mg daily), oral minoxidil (5mg daily), Polaris NR02 shampoo, and ketoconazole 2% shampoo. They plan to continue the regimen and consider a hair transplant in the future, with no reported side effects from the current treatment.

A user shared their 4-month progress using a topical solution with 5% minoxidil and 0.1% finasteride, applied twice daily. They reported good results despite occasional missed applications.

The conversation discusses a hair loss treatment regimen including finasteride, dutasteride, minoxidil, tretinoin, microneedling, and red light therapy. The user plans to update on progress after eight months.

An 18-year-old is experiencing positive hair regrowth results using 2.5mg minoxidil, 0.5mg finasteride daily, and dermarolling twice a week. They are satisfied with the progress and hope for continued improvement.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

User shared progress after 4 months using topical minoxidil and oral finasteride, reporting noticeable regrowth and no side effects. Other users discussed their experiences and advice on similar treatments, including dutasteride and derma stamping.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

PP405 is expected to work for hair regrowth by reactivating stem cells in hair follicles, with FDA approval anticipated in 2027-28. Users express both optimism and skepticism about its effectiveness and the lengthy approval process.

A 26-year-old male shared progress pictures after 4 months of using a compounded spray with minoxidil, finasteride, and tretinoin, along with dermastamping and ketoconazole shampoo, noting minimal visible change but expecting results soon. Users commented on noticeable progress from bald to having hair and inquired about the treatment composition.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

The user is pleased with their 4-month hair growth progress using a daily Locklab 4-in-1 pill containing minoxidil, finasteride, dutasteride, and biotin, with no side effects reported. Another user discusses the effectiveness of oral versus topical minoxidil and suggests adding tretinoin to enhance results.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A 20-year-old shares progress in combating hair loss using minoxidil and microneedling, with plans to add finasteride. Users suggest starting finasteride or dutasteride to maintain results and control DHT levels.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

A user shared their 4-month progress using 1mg finasteride and minoxidil foam once a day for hair loss. Another user complimented the results and asked about their age.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

The conversation is about skepticism regarding hair growth results after 4 months of using finasteride and minoxidil. Many users doubt the authenticity of the progress pictures, suggesting the hair growth is too rapid to be real.